Several companies in the pharmaceutical and healthcare industry have unveiled new and innovative digital biomarker technologies for tracking people infected with COVID-19.
Biofourmis’ artificial intelligence (AI)-powered Biovitals Sentinel platform is one such technology unveiled by the company. The technology was used in Hong Kong for identifying potential COVID-19 cases as well as monitoring associated symptoms. The platform helped in addressing the need to use remote patient monitoring (RPM) approach due to the pandemic situation.
The University of Hong Kong administered the programme leveraging FDA-cleared Biovitals technology to enable continuous monitoring of patients diagnosed with COVID-19 and providing analytical capacity for clinician decision support. Biofourmis’ joint venture partner for the China region, Harmony Medical, was also associated with the programme.
The 24/7 remote monitoring technology and analytics are devised to provide the operator with real-time updates on coronavirus related symptoms enabling swift intervention in case of deterioration, thereby preventing further exacerbation.
The programme also utilised Biofourmis’ clinical-grade wearable biosensor called Everion for monitoring COVID-19 related symptoms. The biosensor is equipped with optical, temperature, electrodermal, accelerometer, and barometer sensors to measure more than 20 physiological signals such as temperature, blood oxygenation, heart rate and blood pulse wave. The sensor can also check heart rate variability, respiration rate, and inter-beat-interval among others.
The biosensor will also help in developing a better understanding of the novel coronavirus and its behaviour as clinicians and researchers are still working to identify how the disease affects the body. The Everion biosensor can trigger alerts for potential physiological changes that may indicate disease progression.
Apart from Biofourmis, companies such as Huma, Oura, and Kinsa Health have introduced or modified their platforms to enable remote monitoring of patients when conventional settings are unavailable or unfeasible.